Athira Pharma, Inc. (NASDAQ:LONA) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Athira Pharma, Inc. (NASDAQ:LONA) have been assigned an average recommendation of “Hold” from the five brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $15.00.

LONA has been the topic of several research reports. Cantor Fitzgerald initiated coverage on Athira Pharma in a report on Thursday, February 26th. They issued an “overweight” rating on the stock. Zacks Research raised Athira Pharma to a “hold” rating in a report on Friday, February 27th. Piper Sandler initiated coverage on Athira Pharma in a report on Wednesday, May 27th. They issued an “overweight” rating and a $20.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a report on Monday, May 11th. Finally, Wall Street Zen upgraded shares of Athira Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th.

Athira Pharma Price Performance

NASDAQ LONA opened at $8.18 on Friday. The company has a market capitalization of $76.84 million, a PE ratio of -1.57 and a beta of 1.97. Athira Pharma has a 1 year low of $2.85 and a 1 year high of $14.21. The firm has a fifty day moving average of $9.24.

Athira Pharma (NASDAQ:LONA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.73) earnings per share (EPS) for the quarter. On average, sell-side analysts predict that Athira Pharma will post -3.12 earnings per share for the current year.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.